Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis (SSc–ILD). The CX3CR1/CX3CL1-biological axis may be involved in recruiting antibody secreting plasma cells to SSc lungs, thereby contributing to the immune–mediated pathobiology of SSc–ILD. PubMed, PLoS One, 2018 Nov 20;13(11):e0206545. (Also see Pulmonary Fibrosis Diagnosis)
Short–term progression of interstitial lung disease (ILD) in systemic sclerosis (SSc) predicts long–term survival in two independent clinical trial cohorts. These findings suggest that short–term changes in surrogate measures of SSc–ILD progression may have important effects on long–term outcomes. PubMed, Ann Rheum Dis, 11/08/2018. (Also see Pulmonary Fibrosis)
Mutations of FAM111B gene are not associated with Systemic Sclerosis (SSc). One rare variant was found in a patient with SSc but has no functional or structural impact on the FAM111B gene. PubMed, Sci Rep, 2018 Oct 30;8(1):15988. (Also see Genetics)
Comparison of 2-D shear wave elastography with clinical score in localized scleroderma (LS): A new method to increase the diagnostic accuracy. As non–invasive methods, mean shear wave velocity and dermal thickness by ultrasonography may provide reliable information to diagnose LS. PubMed, J Dermatol, 12/03/2018. (Also see Localized Scleroderma)
Severe gastrointestinal disease (GI) in very early systemic sclerosis (SSc) is associated with early mortality. Severe GI disease is common in early SSc and is associated with significant morbidity and increased mortality. PubMed, Rheumatology (Oxford), 12/04/2018. (Also see Gastrointestinal Involvement)
A 26–Year Experience with Microsurgical Reconstruction of Hemifacial Atrophy and Linear Scleroderma. Patients treated early in their disease course have immediate and sustained correction of their deformity, with slowing or in most cases cessation of the disease process. PubMed, Plast Reconstr Surg, 2018 Nov;142(5):1275-1283. (Also see Parry Rombergs Syndrome and Linear Scleroderma)
Prevalence and Clinical Associations of Antiphospholipid Antibodies (aPL) in Systemic Sclerosis (SSc): New Data From a French Cross–Sectional Study, Systematic Review, and Meta–Analysis. In our SSc population, aPL positivity was associated with venous thrombosis and miscarriage and these data provide additional insights into the role of aPL in the vasculopathy observed in SSc. PubMed, Front Immunol, 2018 Nov 2;9:2457. (Also see Antiphospholipid Syndrome)
Case Report: Complete heart block (CHB) in systemic sclerosis (SSc). Pacemaker implantation might be unavoidable if CHB is secondary to SSc, even if it is asymptomatic. PubMed, Medicine (Baltimore), 2018 Nov;97(46):e13226. (Also see Complications with Heart Involvement)
Exploring Novel Treatment for Scleroderma–Associated Interstitial Lung Disease. This study is one of three major multicenter trials in which Cleveland Clinic’s Rheumatic Lung Disease Program is participating. Consult QD, 12/13/2018. (Also see Treatments for Pulmonary Fibrosis and Clinical Trials)
Analysis of serum macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase in systemic sclerosis (SSc). Although not significantly linked to specific clinical parameters, serum MIF was significantly higher in SSc patients than in healthy controls and systemic lupus erythematosus patients. PubMed, Clin Transl Immunology, 2018 Dec 6;7(12):e1042. (Also see Cytokines)
TOLL FREE HOTLINE, U.S. and Canada: 1-800-564-7099
Ask for our Free Info Packet by email or postal mail!
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: